ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Bioassay Backlog Catch Up Planned By Mid-February

August 26, 1977

Letters: Alternatives Needs Scrutiny, Investigator Open-Mindedness

December 3, 1993

Trial Needed Of PSA To Determine Patients To Test, Chabner Says

March 5, 1993

In Brief: Resolution wasn’t Strong Enough, Reizen Though; Two More chemicals reported Out of Bioassay

June 3, 1977

ASSIST Smoking Intervention gets Under Way In 1991

December 1, 1989

FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings.

August 8, 2008